The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control

Nephropathy progression is slowed and cardiovascular events reduced in patients with stage 3 or higher chronic kidney disease when blood pressure is controlled using combinations of renin┬ľangiotensin system (RAS) blockers with dihydropyridine calcium channel blockers or diuretics. We discuss a trial comparing high-dose RAS blockade with lower-dose RAS blockade combined with a dihydropyridine calcium channel blocker. The primary outcome was cardiovascular events. The combination group had better blood pressure control and fewer total events.

Additional Info

  • Language:
    English
  • Contains Audio:
    No
  • Content Type:
    Articles
  • Source:
    KI
  • Year:
    2013
  • Members Only:
    No



Read 1880 times



Last modified on Friday, 28 March 2014 13:23

Scroll to Top